New drug aimed at saving lives after stem cell transplants
NCT ID NCT07347990
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called iptacopan in 30 people who have a serious blood vessel problem after a stem cell transplant. The drug aims to block a part of the immune system that damages blood vessels. Researchers will check if it helps patients live longer and recover organ function over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iptacopan
What this could lead to
If it works, this could offer a new treatment option for a serious complication after stem cell transplants, potentially improving survival and organ function.
What could go wrong
This is a small, early-phase study with only 30 participants and no comparison group. The drug may not work as hoped, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China, 310003, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••